Get the Stockscreener App
12.54
2.69%
-0.3968
Nurix Therapeutics Inc stock is traded at $12.54, with a volume of 860.83K.
It is down -2.69% in the last 24 hours and up +34.24% over the past month.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
See More
Previous Close:
$12.94
Open:
$12.72
24h Volume:
860.83K
Relative Volume:
0.74
Market Cap:
$958.67M
Revenue:
$54.55M
Net Income/Loss:
$-193.57M
P/E Ratio:
-4.3402
EPS:
-2.89
Net Cash Flow:
$-181.86M
1W Performance:
+5.11%
1M Performance:
+34.24%
6M Performance:
+11.73%
1Y Performance:
-48.54%
1-Day Range:
$12.28
$13.19
1-Week Range:
$11.37
$13.23
52-Week Range:
$8.18
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Compare NRIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
12.54 | 1.31B | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.08 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.99 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.78 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Mar-17-25 | Initiated | Leerink Partners | Market Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
Full technical analysis of Nurix Therapeutics Inc. stockDividend Hike & Stepwise Swing Trade Plans - newser.com
Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting - The Manila Times
Nurix (NASDAQ: NRIX) to present NX-5948 data in CLL and Waldenström at ASH - Stock Titan
Analyzing Nurix Therapeutics Inc. with risk reward ratio chartsMarket Volume Report & Daily Entry Point Trade Alerts - newser.com
What to expect from Nurix Therapeutics Inc. in the next 30 daysStop Loss & Fast Momentum Entry Tips - newser.com
How sustainable is Nurix Therapeutics Inc. stock dividend payoutJuly 2025 Setups & Verified Technical Signals - newser.com
Is Nurix Therapeutics Inc. stock ready for breakout2025 Major Catalysts & Technical Entry and Exit Tips - newser.com
Is Nurix Therapeutics Inc. stock a buy for dividend growthBuy Signal & Momentum Based Trading Ideas - newser.com
Signal strength of Nurix Therapeutics Inc. stock in tech scannersWeekly Market Summary & Expert-Curated Trade Recommendations - newser.com
Nurix Therapeutics Inc. stock daily chart insightsJuly 2025 Retail & AI Enhanced Trade Execution Alerts - newser.com
Can Nurix Therapeutics Inc. recover in the next quarterExit Point & Fast Exit and Entry Trade Guides - newser.com
Will Nurix Therapeutics Inc. stock deliver consistent dividendsWeekly Trend Report & Daily Technical Forecast Reports - newser.com
Visual trend scoring systems applied to Nurix Therapeutics Inc.Weekly Profit Summary & AI Powered Trade Plan Recommendations - newser.com
Why Nurix Therapeutics Inc. stock is seen as undervalued2025 Biggest Moves & Short-Term Trading Opportunity Alerts - newser.com
How institutional ownership impacts Nurix Therapeutics Inc. stockOptions Play & High Accuracy Swing Trade Signals - newser.com
Is Nurix Therapeutics Inc. building a consolidation baseAnalyst Upgrade & Safe Investment Capital Preservation Plans - newser.com
How moving averages guide Nurix Therapeutics Inc. tradingDollar Strength & AI Enhanced Execution Alerts - newser.com
Can Nurix Therapeutics Inc. stock hit record highs againTrade Signal Summary & Fast Exit and Entry Trade Guides - newser.com
Will Nurix Therapeutics Inc. stock go up soonJuly 2025 Market Mood & AI Based Buy/Sell Signal Reports - newser.com
Nurix Therapeutics (NASDAQ:NRIX) CFO Houte Hans Van Sells 3,130 Shares - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Insider Sells $52,313.60 in Stock - MarketBeat
Nurix Therapeutics Advances NX-5948 Study in B-cell Malignancies - MSN
Will Nurix Therapeutics Inc. bounce back from current supportPortfolio Performance Report & High Accuracy Buy Signal Tips - newser.com
Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock - Black Hills Pioneer
Applying chart zones and confluence areas to Nurix Therapeutics Inc.July 2025 Update & Short-Term Trading Opportunity Alerts - newser.com
Nurix Therapeutics CFO van Houte sells $40k in shares By Investing.com - Investing.com UK
Nurix therapeutics CSO Hansen sells $52k in shares By Investing.com - Investing.com UK
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nurix Therapeutics Inc Stock (NRIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| van Houte Hans | Chief Financial Officer |
Oct 30 '25 |
Sale |
12.80 |
3,130 |
40,054 |
43,876 |
| Ring Christine | Chief Legal Officer |
Oct 30 '25 |
Option Exercise |
0.00 |
10,532 |
0 |
54,541 |
| Ring Christine | Chief Legal Officer |
Oct 30 '25 |
Sale |
12.80 |
3,644 |
46,631 |
50,897 |
| Hansen Gwenn | Chief Scientific Officer |
Oct 30 '25 |
Option Exercise |
0.00 |
11,815 |
0 |
80,838 |
| Hansen Gwenn | Chief Scientific Officer |
Oct 30 '25 |
Sale |
12.80 |
4,087 |
52,300 |
76,751 |
| GREGORY JULIA P | Director |
Sep 17 '25 |
Option Exercise |
1.86 |
10,750 |
19,995 |
10,750 |
| van Houte Hans | Chief Financial Officer |
Aug 01 '25 |
Sale |
11.03 |
5,402 |
59,598 |
35,512 |
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):